Albendazole in the treatment of intestinal helminthiasis in children.

Abstract

One hundred sixteen children between 2 and 15 years of age entered a clinical trial of albendazole after examination of their stools revealed ova of one or more intestinal helminths. The drug was administered as a single 400-mg dose (20 ml of 2% suspension) to all the patients except those having Hymenolepis nana infection, who received treatment for three consecutive days. The stools were reexamined on days 7 and 14 posttreatment and after three months for Taenia infections. Patients were considered cured if all parasitological examinations of the feces were negative after treatment. After a single oral dose, albendazole was highly effective in ascariasis (91.9%), ancylostomiasis caused by Ancylostoma duodenale (87.2%), and H nana infection (71.4%). The drug was well tolerated, and no abnormalities were observed in hematological or blood chemistry values. Since the drug is safe and effective as a single-dose treatment of common helminthic infections, it should be considered for mass therapy in the community.

• Authors: R Prasad, P P Mathur, V K Taneja, S C Jagota
• Journal: Clinical therapeutics (Clin Ther) Vol. 7 Issue 2 Pg. 164-8 ( 1985) ISSN: 0149-2918 [Print] United States
• PMID: 3986860 (Publication Type: Journal Article)

Chemical References

• Anthelmintics
• Benzimidazoles
• Albendazole

Topics

• Adolescent
• Albendazole
• Ancylostomiasis (drug therapy)
• Anthelmintics (therapeutic use)
• Ascariasis (drug therapy)
• Benzimidazoles (therapeutic use)
• Child
• Child, Preschool
• Feces (parasitology)
• Female
• Helminthiasis (drug therapy)
• Humans
• Hymenolepiasis (drug therapy)
• Intestinal Diseases, Parasitic (drug therapy)
• Male
• Taeniasis (drug therapy)
• Trichuriasis (drug therapy)